IT201800004419A1 - Medicine to cure gout and procedure for its preparation - Google Patents
Medicine to cure gout and procedure for its preparation Download PDFInfo
- Publication number
- IT201800004419A1 IT201800004419A1 IT102018000004419A IT201800004419A IT201800004419A1 IT 201800004419 A1 IT201800004419 A1 IT 201800004419A1 IT 102018000004419 A IT102018000004419 A IT 102018000004419A IT 201800004419 A IT201800004419 A IT 201800004419A IT 201800004419 A1 IT201800004419 A1 IT 201800004419A1
- Authority
- IT
- Italy
- Prior art keywords
- medicine
- weight
- mixture
- parts
- gout
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 40
- 201000005569 Gout Diseases 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 title claims description 10
- 238000000034 method Methods 0.000 title description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 239000000706 filtrate Substances 0.000 claims description 14
- 241000382455 Angelica sinensis Species 0.000 claims description 8
- 241000561734 Celosia cristata Species 0.000 claims description 8
- 239000010231 banlangen Substances 0.000 claims description 8
- 210000001520 comb Anatomy 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 5
- 235000008504 concentrate Nutrition 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000002662 enteric coated tablet Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- -1 decoction Substances 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 3
- 239000007940 sugar coated tablet Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 241000220436 Abrus Species 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000632227 Antenoron Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
Description
Descrizione dell’Invenzione Industriale avente per titolo: Description of the Industrial Invention entitled:
“Medicina per curare la gotta e procedimento per la sua preparazione” "Medicine to cure gout and procedure for its preparation"
DESCRIZIONE DESCRIPTION
CAMPO TECNICO TECHNICAL FIELD
La presente invenzione si riferisce al campo della medicina, specialmente ad una a medicina per curare la gotta and al procedimento per la sua preparazione. STATO DELLA TECNICA The present invention relates to the field of medicine, especially to a medicine for treating gout and to the procedure for its preparation. STATE OF THE TECHNIQUE
La gotta è una malattia di disturbo metabolico cronico, malattia che è caratterizzata dalla formazione di urato in eccesso nel corpo umano o dalla riduzione dell’escrezione renale dell’acido urico, che causa in tal modo una concentrazione crescente di urato nel sangue, ed è nota a livello clinico come iperuricemia. L’acido urico è un prodotto finale del metabolismo della purina, e la purina è prodotta dal catabolismo delle cellule umane. Se l’acido urico nel sangue aumenta in una certa misura, si depositerà nell’organismo, specialmente nelle giunture e nei reni, causando un attacco ripetuto di artrite, e persino causando disturbi o deformità di movimento nelle giunture, che è noto a livello clinic come artrite della gotta. Il deposito di acido urico nei reni darà come risultato nefrolite da acido urico e danni parenchimali renali, che è noto a livello clinic come nefropatia da acido urico ed è anche noto come nefropatia della gotta: esso può causare un attacco di colica renale, ematuria, idronefrosi e danni alla funzione renale, e persino causare insufficienza renale ed uremia, e così è una delle ragioni principali di morte dei pazienti con gotta. Dato che la gotta è una malattia cronica che dura per tutta la vita e può proseguire per decenni ed ha la caratteristica di un attacco intermittente, un paziente che soffre di gotta tende a prestarvi meno attenzione e non sarà sufficientemente conscio della sua pericolosità. Gout is a disease of chronic metabolic disorder, a disease that is characterized by the formation of excess urate in the human body or by the reduction of renal excretion of uric acid, thereby causing an increasing concentration of urate in the blood, and is known clinically as hyperuricaemia. Uric acid is a final product of purine metabolism, and purine is produced by the catabolism of human cells. If the uric acid in the blood increases to some extent, it will settle in the body, especially in the joints and kidneys, causing a repeated bout of arthritis, and even causing movement disorders or deformities in the joints, which is known clinically. such as gout arthritis. Deposition of uric acid in the kidneys will result in uric acid nephrolitis and renal parenchymal damage, which is known clinically as uric acid nephropathy and is also known as gout nephropathy: it can cause an attack of renal colic, hematuria, hydronephrosis and damage to kidney function, and even cause kidney failure and uremia, and so is one of the main reasons for death of patients with gout. Since gout is a chronic disease that lasts for a lifetime and can continue for decades and has the characteristic of an intermittent attack, a patient suffering from gout tends to pay less attention to it and will not be sufficiently aware of its danger.
Attualmente, la gotta è curate principalmente tramite somministrazione di medicine secondo i sintomi clinici: al paziente vengono principalmente somministrati colchicina e acesodina durante un attacco di gotta, allo scopo di diminuire rapidamente l’infiammazione e alleviare il dolore, mentre al paziente vengono somministrati in modo intermittente purina, ecc. per diminuire l’acido urico, in modo da impedire ancora una volta un attacco. In generale, tutte le medicine occidentali attualmente utilizzate per la cura della gotta hanno effetti collaterali gravi, e sono palliative. In aggiunta, per quanto riguarda la somministrazione intermittente di medicine occidentali, una volta che tale somministrazione viene interrotta, la gotta si ricostituirà rapidamente, per causare in tal modo un attacco di gotta transitiva dovuto allo scioglimento eccessivamente rapido dell’acido urico. Currently, gout is mainly treated by administering medicines according to clinical symptoms: the patient is mainly given colchicine and acesodine during a gout attack, in order to rapidly decrease inflammation and relieve pain, while the patient is given them in a manner intermittent purine, etc. to decrease uric acid, in order to once again prevent an attack. In general, all Western medicines currently used for the treatment of gout have serious side effects, and are palliative. In addition, with regard to the intermittent administration of Western medicines, once this administration is stopped, the gout will quickly reconstitute, thus causing a transitive gout attack due to the excessively rapid dissolution of uric acid.
Tuttavia, gli effetti di cura dei suddetti metodi di cura non sono buoni. In aggiunta, le medicine attuali hanno effetti di tossicità diversi. Pertanto, esiste un’urgente necessità di una nuova medicina per curare la gotta, allo scopo di superare i suddetti difetti. However, the healing effects of the above healing methods are not good. In addition, current medicines have different toxicity effects. Therefore, there is an urgent need for a new medicine to treat gout, in order to overcome the aforementioned defects.
L’INVENZIONE THE INVENTION
Tenendo presente il suddetto problema, la presente invenzione prevede una medicina per curare la gotta in grado di risolvere i suddetti problemi o almeno parte dei suddetti problemi, che è utilizzata per superare i difetti degli scarsi effetti di cura delle medicine nella tecnica anteriore. With the above problem in mind, the present invention provides a medicine for treating gout capable of solving the above problems or at least part of the above problems, which is used to overcome the shortcomings of the poor cure effects of the medicines in the prior art.
Secondo un primo aspetto, la presente invenzione prevede una medicina per curare la gotta comprendente, in parti in peso, Cresta di gallo 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 ed Herba Pyrolae 5-12. According to a first aspect, the present invention provides a medicine for treating gout comprising, in parts by weight, Cockscomb 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 and Herba Pyrolae 5 -12.
La medicina per curare la gotta secondo la presente invenzione ha ingredienti diversi a confronto con le medicine nella tecnica anteriore, e può superare i difetti delle medicine nella tecnica anteriore. The medicine for treating gout according to the present invention has different ingredients compared to the medicines in the prior art, and can overcome the shortcomings of the medicines in the prior art.
DESCRIZIONE DETTAGLIATA DELLE FORME DI REALIZZAZIONE DETAILED DESCRIPTION OF THE FORMS OF REALIZATION
In una forma di realizzazione della presente invenzione, è prevista una medicina per curare la gotta, comprendente in parti in peso, Cresta di gallo 5-15, Herba Lysimachiae (“Longhairy Antenoron Herb”) 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 ed Herba Pyrolae 5-12. In one embodiment of the present invention, a medicine for treating gout is provided, comprising in parts by weight, Cockscomb 5-15, Herba Lysimachiae ("Longhairy Antenoron Herb") 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 and Herba Pyrolae 5-12.
In aggiunta, la medicina comprende inoltre, in parti in peso, Carapax Eretmochelyos 20-30. In addition, the medicine also includes, in parts by weight, Carapax Eretmochelyos 20-30.
In aggiunta, the medicina comprende inoltre, in parti in peso, Rhizoma Smilacis Glabrae 12-18. In addition, the medicine also includes, in parts by weight, Rhizoma Smilacis Glabrae 12-18.
I suddetti Carapax Eretmochelyos e Rhizoma Smilacis Glabrae sono solo alcuni esempi specifici, ma non sono intesi come limitazione: sono possibili anche altri materiali, quali frutta di “wolfberry”, Gynostemma pentaphyllum, 12 Semen Astragali Complanati, Radix Dipsaci, Herba Eclipta, Fructus Ligustri Lucidi, ecc. Gli altri possibili materiali non saranno descritti in dettaglio. The aforementioned Carapax Eretmochelyos and Rhizoma Smilacis Glabrae are just some specific examples, but they are not intended as a limitation: other materials are also possible, such as "wolfberry" fruit, Gynostemma pentaphyllum, 12 Semen Astragali Complanati, Radix Dipsaci, Herba Eclipta, Fructus Ligustri Transparencies, etc. The other possible materials will not be described in detail.
A scelta, in una forma di realizzazione della presente invenzione, si possono aggiungere materialiper rinvigorire la circolazione del sangue, quali Carcuma Longa, Ligusticum Chuanxiong Hort, Radix Salviae Miltiorrhizae ed enotera. Optionally, in an embodiment of the present invention, blood circulation reinvigorating materials can be added, such as Carcuma Longa, Ligusticum Chuanxiong Hort, Radix Salviae Miltiorrhizae and evening primrose.
In aggiunta, in una forma di realizzazione della presente invenzione, allo scopo di migliorare l’effetto farmacologico, la medicina può comprendere inoltre materiali per eliminare il calore, quali Fructus Gardeniae, Flos Chrysanthemi, Semen Cassiae, Cortex Fraxini, Radix Sophorae Flavescentis, Flos Chrysanthemi Indici, Andrographis Paniculata, ecc. In addition, in an embodiment of the present invention, in order to improve the pharmacological effect, the medicine may further comprise heat-eliminating materials, such as Fructus Gardeniae, Flos Chrysanthemi, Semen Cassiae, Cortex Fraxini, Radix Sophorae Flavescentis, Flos Chrysanthemi Indices, Andrographis Paniculata, etc.
In aggiunta, la medicina può comprendere inoltre materiali per eliminare l’umidità e facilitare la diuresi, quali Herba Sedi, l’erba Abrus, ecc. In addition, the medicine may also include materials to eliminate moisture and facilitate diuresis, such as Herba Sedi, Abrus grass, etc.
In aggiunta, la medicina può comprendere inoltre materiali per riscaldare l’interno, quali il pepe. In addition, the medicine may also include materials for heating the inside, such as pepper.
In una forma di realizzazione della presente invenzione, la forma di dosaggio della medicina è almeno una tra compressa rivestita da pellicola, compressa rivestita di zucchero, compressa rivestita enterica, compressa disperdibile, capsula, granulo, decotto, miscela, sciroppo, iniezione, soluzione orale e liquido torbido orale. In one embodiment of the present invention, the dosage form of the medicine is at least one of film-coated tablet, sugar-coated tablet, enteric-coated tablet, dispersible tablet, capsule, granule, decoction, mixture, syrup, injection, oral solution and cloudy oral liquid.
In una forma di realizzazione della presente invenzione, a scelta, la medicina ha una forma di dosaggio per somministrazione orale. In one embodiment of the present invention, optionally, the medicine has a dosage form for oral administration.
In una forma di realizzazione della presente invenzione, a scelta, la forma di dosaggio per somministrazione orale comprende compressa, capsula, pillola, iniezione, preparato a rilascio sostenuto, e preparato a rilascio controllato. In one embodiment of the present invention, optionally, the dosage form for oral administration comprises tablet, capsule, pill, injection, sustained release preparation, and controlled release preparation.
La medicina della forma di realizzazione prevista nella presente invenzione, oppure la composizione medicinale che comprende la stessa, può essere somministrata in una forma di dosaggio unitaria attraverso tratto intestinale, cavità nasale, mucosa orale, occhi, polmoni, tratto respiratorio, pelle, retto, ecc., e può essere somministrata tramite somministrazione orale, iniezione intravenosa, iniezione intramuscolare, e iniezione sottocutanea. The medicine of the embodiment contemplated in the present invention, or the medicinal composition comprising the same, can be administered in a unit dosage form via the intestinal tract, nasal cavity, oral mucosa, eyes, lungs, respiratory tract, skin, rectum, etc., and can be administered via oral administration, intravenous injection, intramuscular injection, and subcutaneous injection.
La forma di dosaggio di somministrazione può essere una forma di dosaggio liquida, una forma di dosaggio solida o una forma di dosaggio semi-solida. La forma di dosaggio liquida può essere una soluzione, emulsione, sospensione, iniezione (comprese iniezione d’acqua, iniezione di polvere e trasfusione), gocce per occhi, gocce nasali, lozione e linimento; la forma di dosaggio solida può essere compressa (comprese compressa non rivestita, compressa rivestita enterica, compressa per la bocca, compressa disperdibile, compressa masticabile, compressa effervescente, compressa a disintegrazione orale), capsula (comprese capsula dura, capsula morbida, capsula enterica), granulo, polvere, pallina, pillola a caduta, supposta, agente di pellicola, pasta, aerosol, spray, ecc.; e la forma di disaggio semi-solida può essere unguento, gel, pasta, ecc. La forma di dosaggio della medicina è preferibilmente compressa, capsule, pillola ed iniezione. The dosage form of administration can be a liquid dosage form, a solid dosage form or a semi-solid dosage form. The liquid dosage form can be a solution, emulsion, suspension, injection (including water injection, powder injection and transfusion), eye drops, nasal drops, lotion and liniment; solid dosage form can be tablet (including uncoated tablet, enteric coated tablet, oral tablet, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet), capsule (including hard capsule, soft capsule, enteric capsule) , granule, powder, pellet, drop pill, suppository, film agent, paste, aerosol, spray, etc .; and the semi-solid form of disage can be ointment, gel, paste, etc. The dosage form of the medicine is preferably tablet, capsule, pill and injection.
La medicina secondo una forma di realizzazione della presente invenzione può essere preparata in un preparato convenzionale, un preparato a rilascio sostenuto, un preparato a rilascio controllato, un preparato per obiettivi, e vari preparati di somministrazione di granuli. The medicine according to an embodiment of the present invention can be prepared in a conventional preparation, a sustained release preparation, a controlled release preparation, a targeting preparation, and various bead delivery preparations.
In una forma di realizzazione della presente invenzione, allo scopo di preparare la medicina della presente invenzione in compresse, si possono utilizzare vari eccipienti quali diluenti, leganti, umettanti, agenti disintegranti, lubrificanti ed agenti scivolanti. I diluenti possono essere amido, destrina, saccarosio, lattosio, mannitolo, sorbitolo, xilitolo, cellulosa microcristallina, solfato di calcio, idrogeno fosfato di calcio, carbonato di calcio e simili; l’umettante può essere acqua, etanolo, iso-propanolo e simili; il legante può essere polpa di amido, destrina, sciroppo, miele, soluzione di glucosio, cellulosa microcristallina, polpa di gomma arabica, polpa di gelatina, carbossimetilcellulosa e metilcellulosa; l’agente disintegrante può essere amido secco, cellulosa microcristallina, idrossi-propilcellulosa a bassi sostituenti; ed il lubrificante e l’agente scivolante può essere talco, silice, stearato, paraffina liquida e simili. In an embodiment of the present invention, in order to prepare the medicine of the present invention in tablets, various excipients such as diluents, binders, humectants, disintegrating agents, lubricants and sliding agents can be used. The diluents can be starch, dextrin, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate and the like; the humectant can be water, ethanol, iso-propanol and the like; the binder can be starch pulp, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, gum arabic pulp, gelatin pulp, carboxymethyl cellulose and methyl cellulose; the disintegrating agent can be dry starch, microcrystalline cellulose, hydroxy-propylcellulose with low substituents; and the lubricant and the sliding agent can be talc, silica, stearate, liquid paraffin and the like.
Inoltre, la medicina può essere anche una compressa rivestita, per esempio una compressa rivestita di zucchero, una compressa rivestita da pellicola, una compressa rivestita enterica e simili. Furthermore, the medicine may also be a coated tablet, for example a sugar-coated tablet, a film-coated tablet, an enteric-coated tablet and the like.
Quando la medicina è preparata in una capsula, l’ingrediente attivo può essere preparato in granuli o palline con l’aggiunta di un diluente, un legante ed un agente disintegrante, che sono quindi collocati in una capsula dura o una capsula morbida. When the medicine is prepared in a capsule, the active ingredient can be prepared in granules or balls with the addition of a diluent, a binder and a disintegrating agent, which are then placed in a hard capsule or a soft capsule.
Quando la medicina è preparata in un’iniezione, il solvente può essere costituito da acqua, etanolo, iso-propanolo, propilen glicole, o una loro miscela. When the medicine is prepared in an injection, the solvent can consist of water, ethanol, iso-propanol, propylene glycol, or a mixture thereof.
Inoltre, si può aggiungere una quantità appropriata di agente solubilizzante, cosolvente, agente di regolazione del pH, agente di regolazione della pressione osmotica. In addition, an appropriate amount of solubilizing agent, cosolvent, pH adjusting agent, osmotic pressure regulating agent can be added.
Inoltre, la medicina può avere aggiunti coloranti, conservanti, profumi, sostanze correttive o altri additivi. In addition, the medicine may have added dyes, preservatives, perfumes, corrective substances or other additives.
In una forma di realizzazione della presente invenzione, è previsto un procedimento per preparare la suddetta medicina, comprendente le seguenti fasi: una prima fase: pesare, in parti in peso, Cresta di gallo 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 ed Herba Pyrolae 5-12, mescolare per ottenere una miscela, e polverizzare la miscela; In an embodiment of the present invention, a process is provided for preparing the aforementioned medicine, comprising the following steps: a first step: weighing, in parts by weight, Cockscomb 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 and Herba Pyrolae 5-12, mix to obtain a mixture, and pulverize the mixture;
una seconda fase: aggiungere il 70% di etanolo nella miscela polverizzata ad un rapporto in peso di (2-3):1; a second step: adding 70% of ethanol to the pulverized mixture at a weight ratio of (2-3): 1;
una terza fase: estrarre a riflusso la sostanza risultante due volte, ciascuna per 2-3 h, e filtrare per ottenere due filtrati; e a third step: refluxing the resulting substance twice, each for 2-3 h, and filtering to obtain two filtrates; And
una quarta fase: mescolare i due filtrati, e concentrare per rimuovere l’etanolo per ottenere una soluzione di estrazione come preparato medicinale obiettivo. a fourth phase: mix the two filtrates, and concentrate to remove the ethanol to obtain an extraction solution as a target medicinal preparation.
Qui di seguito, sono forniti parecchi esempi specifici del procedimento per preparare la medicina per curare la gotta. Below, several specific examples of the procedure for preparing medicine to treat gout are given.
Esempio 1 Example 1
una prima fase: pesare, in parti in peso, Cresta di gallo 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 ed Herba Pyrolae 5-12, mescolare per ottenere una miscela, e polverizzare la miscela; a first phase: weigh, in parts by weight, Cockscomb 5-15, Herba Lysimachiae 10-15, Radix Isatidis 13-20, Angelica Sinensis 12-28 and Herba Pyrolae 5-12, mix to obtain a mixture, and pulverize the mixture;
una seconda fase: preparare la miscela come decotto con acqua due volte, ciascuna per 4 h a 30 °C aggiungendo 10 ml d’acqua ad un intervallo di 30 minuti, e filtrate per ottenere due filtrati; a second phase: prepare the mixture as a decoction with water twice, each for 4 hours at 30 ° C by adding 10 ml of water at an interval of 30 minutes, and filtered to obtain two filtrates;
una terza fase: mescolare i due filtrati, ed aggiungere il 70% di etanolo, in cui il peso dell’etanolo è il doppio del peso totale delle materie prime; a third phase: mix the two filtrates, and add 70% ethanol, in which the weight of ethanol is double the total weight of the raw materials;
una quarta fase: estrarre a riflusso il prodotto risultante due volte, ciascuna per 2 h, e filtrare per ottenere due filtrati; a fourth step: refluxing the resulting product twice, each for 2 h, and filtering to obtain two filtrates;
una quinta fase: mescolare i due filtrati, e concentrare per rimuovere l’etanolo per ottenere una soluzione di estrazione come preparato medicinale obiettivo. a fifth phase: mix the two filtrates, and concentrate to remove the ethanol to obtain an extraction solution as a target medicinal preparation.
Esempio 2 Example 2
una prima fase: pesare, in parti in peso, Cresta di gallo 5, Herba Lysimachiae 10, Radix Isatidis 13, Angelica Sinensis 28 ed Herba Pyrolae 12; a first phase: weigh, in parts by weight, Cockscomb 5, Herba Lysimachiae 10, Radix Isatidis 13, Angelica Sinensis 28 and Herba Pyrolae 12;
una seconda fase: polverizzare i suddetti materiali in una polvere fine, filtrare con un vaglio a 200 maglie, e mescolare in modo uniforme per ottenere una miscela polverizzata; a second phase: pulverizing the aforesaid materials into a fine powder, filtering with a 200 mesh sieve, and mixing evenly to obtain a pulverized mixture;
una terza fase: aggiungere il 70% di etanolo nella miscela polverizzata ad un rapporto in peso di 3:1; a third step: adding 70% of ethanol to the pulverized mixture at a weight ratio of 3: 1;
una quarta fase: estrarre a riflusso il prodotto risultante due volte, ciascuna per 3 h, e filtrare per ottenere due filtrati; e a fourth step: refluxing the resulting product twice, each for 3 h, and filtering to obtain two filtrates; And
una quinta fase: mescolare i due filtrati, e concentrare per rimuovere l’etanolo per ottenere una soluzione di estrazione come preparato medicinale obiettivo. a fifth phase: mix the two filtrates, and concentrate to remove the ethanol to obtain an extraction solution as a target medicinal preparation.
Esempio 3 Example 3
una prima fase: pesare, in parti in peso, Cresta di gallo 5, Herba Lysimachiae 10, Radix Isatidis 13, Angelica Sinensis 28 ed Herba Pyrolae 12; a first phase: weigh, in parts by weight, Cockscomb 5, Herba Lysimachiae 10, Radix Isatidis 13, Angelica Sinensis 28 and Herba Pyrolae 12;
una seconda fase: polverizzare i suddetti materiali in una polvere fine, filtrare con un vaglio a 200 maglie, e mescolare in modo uniforme per ottenere una miscela polverizzata; a second phase: pulverizing the aforesaid materials into a fine powder, filtering with a 200 mesh sieve, and mixing evenly to obtain a pulverized mixture;
una terza fase: aggiungere acqua nella suddetta miscela polverizzata, ed impregnare per almeno 8 h fino a quando la miscela non è completamente imbevuta; a third phase: add water to the above pulverized mixture, and soak for at least 8 hours until the mixture is completely soaked;
una quarta fase: preparare la miscela come decotto con acqua due volte, ciascuna per 4 h a 30 °C aggiungendo 10 ml d’acqua ad un intervallo di 30 minuti, filtrare per ottenere due filtrati; a fourth phase: prepare the mixture as a decoction with water twice, each for 4 hours at 30 ° C by adding 10 ml of water at an interval of 30 minutes, filter to obtain two filtrates;
una quinta fase: mescolare i due filtrati, ed aggiungere il 70% di etanolo, in cui il peso dell’etanolo è tre volte il peso totale delle materie prime; a fifth phase: mix the two filtrates, and add 70% ethanol, in which the weight of ethanol is three times the total weight of the raw materials;
una sesta fase: estrarre a riflusso il prodotto risultante due volte, ciascuna per 3 h, e filtrare per ottenere due filtrati; e a sixth step: refluxing the resulting product twice, each for 3 h, and filtering to obtain two filtrates; And
una settima fase: mescolare i due filtrati, e concentrare per rimuovere l’etanolo per ottenere una soluzione di estrazione come preparato medicinale obiettivo. a seventh phase: mix the two filtrates, and concentrate to remove the ethanol to obtain an extraction solution as a target medicinal preparation.
La medicina per curare la gotta secondo la presente invenzione ha ingredienti diversi a confronto con le medicine nella tecnica anteriore, e può superare i difetti delle medicine nella tecnica anteriore. The medicine for treating gout according to the present invention has different ingredients compared to the medicines in the prior art, and can overcome the shortcomings of the medicines in the prior art.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000004419A IT201800004419A1 (en) | 2018-04-12 | 2018-04-12 | Medicine to cure gout and procedure for its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000004419A IT201800004419A1 (en) | 2018-04-12 | 2018-04-12 | Medicine to cure gout and procedure for its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201800004419A1 true IT201800004419A1 (en) | 2018-07-12 |
Family
ID=62875130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102018000004419A IT201800004419A1 (en) | 2018-04-12 | 2018-04-12 | Medicine to cure gout and procedure for its preparation |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT201800004419A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926855A (en) * | 2010-08-25 | 2010-12-29 | 肖富洲 | Medicinal tea for reducing uric acid of patient with gout |
| CN103169900B (en) * | 2013-04-16 | 2014-11-05 | 董慧芳 | Chinese herba preparation for treating gout |
| CN104435893A (en) * | 2014-12-11 | 2015-03-25 | 赵玉 | Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition |
| CN106139009A (en) * | 2016-08-03 | 2016-11-23 | 韩洁茹 | A kind of Chinese medicine composition purposes in the medicine of preparation treatment chronic gout |
| CN107260781A (en) * | 2017-05-05 | 2017-10-20 | 广州智润生物制药科技有限公司 | It is a kind of to treat pharmaceutical composition of gout and preparation method thereof |
| CN107715014A (en) * | 2017-10-31 | 2018-02-23 | 南宁市共健源健康科技有限公司 | A kind of Chinese medicine composition for gout and preparation method thereof |
-
2018
- 2018-04-12 IT IT102018000004419A patent/IT201800004419A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926855A (en) * | 2010-08-25 | 2010-12-29 | 肖富洲 | Medicinal tea for reducing uric acid of patient with gout |
| CN103169900B (en) * | 2013-04-16 | 2014-11-05 | 董慧芳 | Chinese herba preparation for treating gout |
| CN104435893A (en) * | 2014-12-11 | 2015-03-25 | 赵玉 | Gout-resisting, inflammation-resisting, blood circulation-promoting and blood stasis-removing and pain-alleviating traditional Chinese medicine composition |
| CN106139009A (en) * | 2016-08-03 | 2016-11-23 | 韩洁茹 | A kind of Chinese medicine composition purposes in the medicine of preparation treatment chronic gout |
| CN107260781A (en) * | 2017-05-05 | 2017-10-20 | 广州智润生物制药科技有限公司 | It is a kind of to treat pharmaceutical composition of gout and preparation method thereof |
| CN107715014A (en) * | 2017-10-31 | 2018-02-23 | 南宁市共健源健康科技有限公司 | A kind of Chinese medicine composition for gout and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| CHEN HAIYAN ET AL: "The effect of resveratrol on the recurrent attacks of gouty arthritis", CLINICAL RHEUMATOLOGY, ACTA MEDICA BELGICA, BRUXELLES, BE, vol. 35, no. 5, 3 December 2014 (2014-12-03), pages 1189 - 1195, XP035892554, ISSN: 0770-3198, [retrieved on 20141203], DOI: 10.1007/S10067-014-2836-3 * |
| YONGPING GUO ET AL: "Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY., vol. 37, no. 4, 1 January 2015 (2015-01-01), CH, pages 1491 - 1502, XP055536734, ISSN: 1015-8987, DOI: 10.1159/000438517 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IT201800004419A1 (en) | Medicine to cure gout and procedure for its preparation | |
| KR20190107308A (en) | A drug for treating gout and its preparation method | |
| DE102018109092A1 (en) | Drug for the treatment of gout and a method for its production | |
| DE102018102355A1 (en) | MEDICAMENT FOR THE TREATMENT OF GAS AND METHOD FOR THE PRODUCTION THEREOF | |
| JP2019172596A (en) | Drug for treating gout and preparation method thereof | |
| DE102018120298A1 (en) | A medicine used to treat gout and process for its manufacture | |
| CN105535442B (en) | A kind of Chinese materia medica preparation for treating maintenance hemodialysis patients with chronic renal failure peripheral neuropathy | |
| KR20190094911A (en) | A drug for treating gout and its preparation method | |
| KR20190099697A (en) | A drug for treating gout and its preparation method | |
| KR20190139053A (en) | A drug for treating shoulder periarthritis and its preparation method | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| FR3081327A1 (en) | DRUG PROCESSING MEDIUM AND METHOD FOR PREPARING THE SAME | |
| KR20190105834A (en) | A drug for treating gout and its preparation method | |
| KR20190114667A (en) | A drug for treating gout and its preparation method | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| KR20190093955A (en) | A drug for treating gout and its preparation method | |
| KR20190093431A (en) | A drug for treating gout and its preparation method | |
| KR20190103892A (en) | A drug for treating gout and its preparation method | |
| KR20230113060A (en) | A drug for treating osteoporosis and its preparation method | |
| IT201800007105A1 (en) | A DRUG TO TREAT GASTROELCOSIS AND ITS METHOD OF PREPARATION | |
| CN110946905B (en) | Traditional Chinese medicine composition applied to acupuncture points of peritoneal dialysis patients and preparation method and application thereof | |
| IT201800005833A1 (en) | Medicine to treat gastroelcosis and its method of preparation | |
| CN102133274A (en) | Chinese medicinal composition | |
| KR20190107871A (en) | A drug for treating gout and its prepration method | |
| DE102018110935A1 (en) | Drug for the treatment of gout and the corresponding manufacturing process |